PHARMACEUTICAL PREPARATION
    1.
    发明申请
    PHARMACEUTICAL PREPARATION 审中-公开
    药物制剂

    公开(公告)号:US20160114063A1

    公开(公告)日:2016-04-28

    申请号:US14896424

    申请日:2014-06-05

    申请人: BAYER AS

    IPC分类号: A61K51/10 A61K9/00

    摘要: The present invention provides a method for generating a purified solution of at least one alpha-emitting radionuclide complex. The method comprises contacting a solution of the alpha-emitting radionuclide complex and at least one daughter nuclide with at least one selective binder for the daughter nuclide and subsequently separating the solution from the selective binder. The invention also provides a method for the removal of at least one daughter radionuclide from a solution comprising at least one alpha-emitting radionuclide complex. The method comprises contacting the solution with at least one selective binder for the daughter nuclide.

    摘要翻译: 本发明提供了一种产生至少一种α发射放射性核素复合物的纯化溶液的方法。 该方法包括将α发射放射性核素复合物和至少一个子核素的溶液与至少一种用于子核素的选择性粘合剂接触,随后将溶液与选择性粘合剂分离。 本发明还提供了一种从包含至少一种α发射放射性核素复合物的溶液中除去至少一种儿子放射性核素的方法。 该方法包括使溶液与至少一种用于子核素的选择性粘合剂接触。

    PHARMACEUTICAL PREPARATION
    2.
    发明申请

    公开(公告)号:US20220023449A1

    公开(公告)日:2022-01-27

    申请号:US17307857

    申请日:2021-05-04

    申请人: Bayer AS

    IPC分类号: A61K51/10 A61K9/00

    摘要: The present invention provides a method for generating purified solution of at least on alpha-emitting radionuclide complex. The method comprises contacting a solution of the alpha-emitting radionuclide complex and at least one daughter nuclide with at least one selective binder for the daughter nuclide and subsequently separating the solution from the selective binder. The invention also provides a method for the removal of at least one daughter radionuclide from a solution comprising at least one alpha-emitting radionuclide complex. The method comprises contacting the solution with at least one selective binder for the daughter nuclide.

    PURIFICATION METHOD
    3.
    发明申请

    公开(公告)号:US20210130253A1

    公开(公告)日:2021-05-06

    申请号:US16903181

    申请日:2020-06-16

    申请人: Bayer AS

    摘要: The invention provides a method for the purification of complexed 227Th from a mixture comprising complexed 227Th and 223Ra (complexed or in solution), said method comprising: i) preparing a first solution comprising a mixture of complexed 227Th ions and 223Ra ions in a first aqueous buffer; ii) loading said first solution onto a separation material; iii) eluting complexed 227Th from said separation material whereby to generate a second solution comprising complexed 227Th; iv) Optionally rinsing said separation material using a first aqueous washing medium; The invention additionally provides a purified 227Th solution, a pharmaceutical product and its use in treatment of disease such as cancer and a kit for generation of such a product.

    PURIFICATION METHOD
    4.
    发明申请
    PURIFICATION METHOD 审中-公开

    公开(公告)号:US20190002363A1

    公开(公告)日:2019-01-03

    申请号:US16067404

    申请日:2016-12-30

    申请人: BAYER AS

    摘要: The invention provides a method for the purification of complexed 227Th from a mixture comprising complexed 227Th and 223Ra (complexed or in solution), said method comprising: i) preparing a first solution comprising a mixture of complexed 227Th ions and 223Ra ions in a first aqueous buffer; ii) loading said first solution onto a separation material; iii) eluting complexed 227Th from said separation material whereby to generate a second solution comprising complexed 227Th; iv) Optionally rinsing said separation material using a first aqueous washing medium; The invention additionally provides a purified 227Th solution, a pharmaceutical product and its use in treatment of disease such as cancer and a kit for generation of such a product.

    ISOTOPE PURIFICATION METHOD
    5.
    发明申请

    公开(公告)号:US20190001005A1

    公开(公告)日:2019-01-03

    申请号:US16067675

    申请日:2016-12-29

    申请人: BAYER AS

    摘要: The invention provides a method for the purification of 227 Th from a mixture comprising 227 Th and 223 Ra, said method comprising: i) preparing a first solution comprising a mixture of 227 Th and 223 Ra ions dissolved in a first aqueous buffer; ii) loading said first solution onto a separation material such as a strong cation exchange resin; iii) eluting 227 Th from the separation material, whereby to generate a second solution comprising 227 Th; iv) Optionally rinsing said separation material using a first aqueous washing medium; The invention additionally provides a method for forming a radio pharmaceutical comprising complexing the purified 227 Th, the pharmaceutical product and its use in treatment of disease such as cancer and a kit for generation of such a product.